Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
80 mg ixekizumab
DRUG
2 trials
Sponsors
Eli Lilly and Company
Conditions
Psoriasis
Phase 3
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
Completed
NCT01624233
Eli Lilly and Company
Psoriasis
Start: 2012-06-30
End: 2017-09-30
Updated: 2019-09-10
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
Completed
NCT01646177
Eli Lilly and Company
Psoriasis
Start: 2012-07-28
End: 2019-07-22
Updated: 2020-07-28
Related Papers
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
Dermatology and Therapy
2024-04-01
4 citations
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
2024-03-23
3 citations
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
2023-07-03
6 citations
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
2022-03-13
9 citations
Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool.
2021-05-28
13 citations
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
2020-11-28
46 citations
Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J).
2020-09-10
9 citations
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
Journal of Drugs in Dermatology
2020-07-01
4 citations
Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab
Journal of the American Academy of Dermatology
2020-02-21
1 citations
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
2018-11-21
11 citations
Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
2018-11-15
50 citations
Long‐term efficacy and safety results from an open‐label phase <scp>III</scp> study (<scp>UNCOVER</scp>‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab
Journal of the European Academy of Dermatology and Venereology
2018-10-16
34 citations
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
Journal of Investigative Dermatology
2018-05-08
52 citations
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
2017-04-01
28 citations
Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3
Journal of the European Academy of Dermatology and Venereology
2016-11-05
82 citations
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
New England Journal of Medicine
2016-06-08
818 citations
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis
JAMA Dermatology
2016-03-08
52 citations
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
2015-06-10
601 citations